

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 29, 2004 Signature: *Sharon M. Sintich*

(Sharon M. Sintich)

Sharon
1644/88
Docket No.: 01017/40451C
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Brockhaus et al.

Confirmation No.: 5613

Application No.: 08/444,791

Art Unit: 1644

Filed: May 19, 1995

Examiner: R. Schwadron, Ph.D.

For: HUMAN TNF RECEPTOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references. Copies of the documents identified on the enclosed PTO/SB/08 form are enclosed, except for copies of the U.S. patent documents which are not enclosed.


In accordance with 37 CFR §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. In accordance with 37 CFR §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits. Our check in the amount of \$180.00 covering the fee set forth in 37 CFR §1.17(p) is enclosed. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 13-2855, under Order No. 01017/40451C. A duplicate copy of this paper is enclosed.

Dated: December 29, 2004

Respectfully submitted,

By


Sharon M. Sintich

Registration No. 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



PTO/SB/08a/b (08-03)


Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	1	of	8	Attorney Docket Number	01017/40451C

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A5	08/478,995	N/A	Lauffler, Leander et al.	
	A6	2003/064480	04-03-2003	Lauffler, Leander et al.	
	A7	4,593,002	01-11-1982	Dulbecco	
	A8	4,675,285	09-19-1984	Clark et al.	
	A9	4,729,326	03-08-1988	Richter	
	A10	4,769,326	09-06-1988	Rutler	
	A11	4,894,439	01-16-1990	Dorin et al.	
	A12	4,912,044	03-27-1990	Jacob et al.	
	A13	4,935,233	06-19-1990	Bell et al.	
	A14	4,963,354	10-06-1990	Shepard et al.	
	A15	4,965,271	10-23-1990	Mandell et al.	
	A16	5,055,447	10-08-1991	Palladino et al.	
	A17	5,073,627	12-17-1991	Curtis et al.	
	A18	5,075,222	12-24-1991	Hannum et al.	
	A19	5,098,702	03-24-1992	Zimmerman et al.	
	A20	5,098,833	03-24-1992	Lasky et al.	
	A21	5,118,500	06-02-1992	Hanel et al.	
	A22	5,136,021	08-04-1992	Dembinski et al.	
	A23	5,155,027	10-13-1992	Sledziewski et al.	
	A24	5,211,395	06-29-1993	Gero	
	A25	5,211,945	05-18-1993	Wallach et al.	
	A26	5,225,538	07-06-1993	Capon et al.	
	A27	5,258,498	11-02-1993	Huston et al.	
	A28	5,264,416	11-23-1993	Park et al.	
	A29	5,270,038	12-14-1993	Klimpel et al.	
	A30	5,336,603	08-09-1994	Capon et al.	
	A31	5,350,683	09-27-1994	Sims et al.	
	A32	5,359,032	10-25-1994	Dayer et al.	
	A33	5,447,851	09-05-1995	Beutler et al.	
	A34	5,455,165	10-03-1995	Capon et al.	
	A35	5,478,925	12-26-1995	Wallach et al.	
	A36	5,512,544	04-30-1996	Wallach et al.	
	A37	5,514,582	05-07-1996	Capon et al.	
	A38	5,599,905	02-04-1997	Mosley et al.	
	A39	5,605,690	02-25-1997	Jacobs et al.	
	A40	5,610,279	03-11-1997	Brockhaus et al.	
	A41	5,633,145	05-27-1997	Feldmann et al.	
	A42	5,639,597	06-17-1997	Lauffer et al.	
	A43	5,695,953	12-09-1997	Wallach et al.	
	A44	5,705,364	01-06-1998	Etcheverry et al.	
	A45	5,712,155	01-27-1998	Smith et al.	
	A46	5,721,121	02-24-1998	Etcheverry et al.	
	A47	5,808,029	09-15-1998	Brockhaus et al.	
	A48	5,811,261	09-22-1998	Wallach et al.	
	A49	5,863,786	01-26-1999	Feldmann et al.	
	A50	5,945,397	08-31-1999	Smith et al.	
Examiner Signature				Date Considered	



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	2	of	8	Attorney Docket Number	01017/40451C


	A51	5,981,701	11-09-1999	Wallach et al.	
	A52	6,143,866	11-07-2000	Brewer et al.	
	A53	6,165,476	12-26-2000	Strom et al.	
	A54	6,201,105	03-13-2001	Smith et al.	
	A55	6,221,675	04-24-2001	Hauptmann et al.	
	A56	6,271,346	08-07-2001	Hauptmann et al.	
	A57	6,294,352	09-25-2001	Hauptmann et al.	
	A58	6,541,610	04-01-2003	Smith	
	A59	6,541,620	04-01-2003	Brewer et al.	
	A60	6,572,852	06-03-2003	Smith et al.	
	A61	RE 36,755	06-27-2000	Smith et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² -Number ³ -Kind Code ⁵ (if known)				
	B13	AU 58976	01-24-1991	Synergen, Inc.		
	B14	EP 120694	10-03-1984	Boss et al.		
	B15	EP 227110	07-01-1987	Satoshi et al.		
	B16	EP 230574	08-05-1987	Ruddle		
	B17	EP 269455	06-01-1988	Ikeyama et al.		
	B18	EP 314317	05-03-1989	Capon et al.		
	B19	EP 325262	07-26-1989	Seed		
	B20	EP 414178	02-27-1991	Seed		
	B21	EP 417563	03-20-1991	Brockhaus et al.		
	B22	EP 460846	12-11-1991	Sims et al.		
	B23	EP 471701	02-26-1992	Lemarie et al.		
	B24	EP 526452	02-10-1993	Capon et al.		
	B25	EP 526905	02-10-1993	Wallach et al.		
	B26	EP 568925	11-10-1993	Wallach et al.		
	B27	EP 606869	07-20-1994	Wallach et al.		
	B28	GB 2,218,101A	10-08-1989	Dayer and Seckinger		
	B29	GB 2 246 569	02-05-1992	Feldman et al.		
	B30	JP 02-154695	06-14-1990	Brockhaus et al.		
	B31	JP 61-293924	12-24-1986	Yojiro et al.		
	B32	WO 91/02078	02-21-1991	Rathjen et al.		
	B33	WO 91/08298	12-13-1991	Capon et al.		
	B34	WO 91/17184	11-14-1991	Carter		
	B35	WO 92/08495	05-29-1992	Gillies		
	B36	WO 92/13095	08-06-1992	Carmichael et al.		
	B37	WO 93/07863	04-29-1993	Mullarkey		
	B38	WO 93/19777	10-14-1993	Smith		
	B39	WO 94/06476	03-31-1994	Smith et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
				Attorney Docket Number	01017/40451C
Sheet	3	of	8		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C31	ABRAHAM et al., p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: ΔΔΔΔΔ JAMA, 19:1531-1538 (1997)		
	C32	ABRAHAM et al., Lenercept (p55 Tumor Necrosis Factor Receptor Fusion Protein) In Severe Sepsis and Early Septic Shock: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial With 1,342 Patients, Crit Care Med, 29:503-510 (2001)		
	C33	AGGARWAL et al., Characterization of Receptors for Human Tumour Necrosis Factor and Their Regulation by γ-Interferon, Nature, 318:665-667 (1985)		
	C34	AGGARWAL et al., Induction of Receptors for Tumor Necrosis Factor-α by Interferons Is Not a Major Mechanism for Their Synergistic Cytotoxic Response, J. Biol. Chem., 262:10000-10007 (1987)		
	C35	AGGARWAL et al., Human tumour necrosis factors: structure and receptor interactions, in Tumor necrosis factor and related cytotoxins, pp.. 39-51, (Ciba Foundation symposium 131), Wiley, Chichester (1987)		
	C36	ARENZANA-SEISDEDOS et al., Immunoregulatory Mediators in the Pathogenesis of Rheumatoid Arthritis, Scand. J. Rheumatol., Supplement 66:13-17 (1987)		
	C37	ARUFFO et al., Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System, Proc. Natl. Acad. Sci. USA, 84:8573-8577 (1987).		
	C38	ASHKENAZI et al., Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoaderhin, Proc. Natl. Acad. Sci., U.S.A. 88:10535-10539 (1991)		
	C39	AYALA, Modern Genetics, Benjamin/Cummings, Publ. Co., Menlo Park CA, p. 45, (1980)		
	C40	BAGLIONI et al., Binding of Human Tumor Necrosis Factor to High Affinity Receptors on HeLa and Lymphoblastoid Cells Sensitive to Growth Inhibition, J. Biol. Chem., 260:13395-13397 (1985)		
	C41	BENJAMINI et al., Antibody Structure, in Immunology: A Short Course, 3rd ed., Wiley-Liss New York, 61-69 (1996)		
	C42	BRANELLEC et al., TNF: Antitumoral Agent at the Border Lines of Immunity and Inflammation, Path. Biol., 39:230-239 (1991)		
	C43	BROCKHAUS et al., Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies, Proc. Natl. Acad. Sci. USA, 87:3127-3131 (1990)		
	C44	CARTER et al., Purification, Cloning, Expression and Biological Characterization of an Interleukin-1 Receptor Antagonist Protein, Nature, 344:633-638 (1990)		
	C45	CARPENTER et al., Epidermal Growth Factor, J. Biol. Chem., 265:7709-7712 (1990)		
	C46	CARPENTER, Receptors For Epidermal Growth Factor And Other Polypeptide Mitogens, Ann. Rev. Biochem., 56:881-914 (1987)		
	C47	CASADEI et al., Expression and Secretion of Aequorin as a Chimeric Antibody by Means of a Mammalian Expression Vector, Proc. Natl. Acad. Sci., U.S.A. 87:2047-2051 (1990)		
	C48	COFFMAN et al., The Role of Helper T Cell Products in Mouse B Cell Differentiation and Isotype Regulation, Immunol. Rev., 102:5-28 (1988)		
	C49	CREASEY et al., A High Molecular Weight Component of the Human Tumor Necrosis Factor Receptor is Associated With Cytotoxicity, Proc. Natl. Acad. Sci. USA, 84:3293-3297 (1987)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
		Application Number	08/444,791-Conf. #5613
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	May 19, 1995
		First Named Inventor	Brockhaus
		Art Unit	1644
		Examiner Name	R. Schwadron, Ph.D.
		Attorney Docket Number	01017/40451C
Sheet	4	of	8

C50	DAYER, Chronic Inflammatory Joint Diseases: Natural Inhibitors of Interleukin 1 and Tumor Necrosis Factor α , J. Rheumatol, 18 (Suppl. 27): 71-75 (1991)
C51	DOWER et al., Human Cytokine Receptors, J. Clin. Immunol., 10:289-299 (1990)
C52	EISENBERG et al., Primary Structure and Functional Expression From Complementary DNA of a Human Interleukin-1 Receptor Antagonist, Nature, 343:341-346 (1990)
C53	ELLISON et al., The Nucleotide Sequence of A Human Immunoglobulin Cy1 Gene, Nucleic Acids Res. 10(13): 4071-79 (1982)
C54	ESMON, The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation, J. Biol. Chem., 264:4743-4746 (1989)
C55	European Search Report for EP 97 12 0664, dated 3/9/98
C56	FELL et al., Genetic Construction And Characterization Of A Fusion Protein Consisting Of A Chimeric F(ab') With Specificity For Carcinomas And Human IL-2, J. Immunol., 146:2446-2452 (1991)
C57	FERNANDEZ-BOTRAN et al., A Soluble, High-Affinity, Interleukin-4-Binding Protein is Present in the Biological Fluids of Mice, Proc. Natl. Acad. Sci., 87:4202-4206 (1990)
C58	FERNANDEZ-BOTRAN, Soluble Cytokine Receptors: Their Role in Immunoregulation, The FASEB Journal, 5:2567-2574 (1991)
C59	FERRANTE et al., Inhibition of Tumour Necrosis Factor Alpha (TNF- α)-Induced Neutrophil Respiratory Burst by a TNF Inhibitor, Immunology, 72:440-442 (1991)
C60	FISHER et al., Cloning And Expression Of Human Tissue Factor cDNA, Thrombosis Research, 48:89-99 (1987)
C61	FISHER et al., Treatment of Septic Shock with the Tumor Necrosis Factor Receptor: Fc Fusion Protein, New Eng. J. Med., 334:1697-1702 (1996)
C62	FOLEY et al., An Inhibitor of the Toxicity of Tumour Necrosis Factor in the Serum of Patients With Sarcoidosis, Tuberculosis and Crohn's Disease, Clin. Exp. Immunol., 80:395-399 (1990)
C63	FOMSGAARD et al., Preliminary Study on Treatment of Septic Shock Patients With Antilipopolysaccharide IgG from Blood Donors, Scand. J. Infect. Dis., 21:697-708 (1989)
C64	GARCIA et al., High Sensitivity of Transgenic Mice Expressing Soluble TNFR1 Fusion Protein to Mycobacterial Infections: Synergistic Action of TNF and IFN- γ in the Differentiation of Protective Granulomas, Eur. J. Immunol., 27:3182-3190 (1997)
C65	GASCOIGNE et al., Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein, Proc. Natl. Acad. Sci USA, 84:2936-2940 (1987)
C66	GEHR et al., Both Tumor Necrosis Factor Receptor Types Mediate Proliferative Signals In Human Mononuclear Cell Activation, J. Immunol., 149:911-917 (1992).
C67	GILLIES et al., Targeting Human Cytotoxic T Lymphocytes To Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells, J. Immunol., 144:1067-1071 (1991)
C68	GOODMAN, Identification of Antigenic Determinants, in Basic & Clinical Immunol., 24-25 (1982)
C69	GOODMAN, Immunogenicity & Antigenic Specificity, in Basic & Clinical Immunol., 101-108 (1991)
C70	GOODWIN et al., Molecular cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor, Molecular and Cellular Biology, 11:3020-3026 (1991)
C71	GRAY et al, Cloning and Expression of cDNA for Human Lymphotoxin, a Lymphokine With Tumour Necrosis Activity, Nature, 312:721-724 (1984)
C72	GRAY et al., Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein, Proc. Natl. Acad. Sci. 87: 7380-84 (1990)
C73	GRUNDMANN et al., Characterization of cDNA Coding for Human Factor XIIIa, Proc. Natl. Acad. Sci. USA, 83:8024-8028 (1986)
C74	HAAK-FRENDSCHO et al., Inhibition of TNF by a TNF Receptor Immunoaderhin, J. Immunol., 152:1347-1353 (1994)

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	5	of	8	Attorney Docket Number	01017/40451C

C75	HANNUM et al., Interleukin-1 Receptor Antagonist Activity of a Human Interleukin-1 Inhibitor, Nature, 343:336-340 (1990)	
C76	HEFLIN et al., Prevention by Granulocyte Depletion of Increased Vascular Permeability of Sheep Lung Following Endotoxemia, J. Clin. Invest., 68:1253-1260 (1981).	
C77	HELLER et al., Amplified Expression of Tumor Necrosis Factor Receptor in Cells Transfected With Epstein-Barr Virus Shuttle Vector cDNA Libraries, J. Biol. Chem., 265:5708-5717 (1990)	
C78	HELLER et al., Amplified Expression of the Tumor Necrosis Factor Receptor in Lymphoblastoid Cells Transfected with HeLa Cell-CDNA Expression Abstract WA 142, Napa Valley Conference 1989	
C79	HIMMLER et al., Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein, DNA and Cell Biology, 9:705-715 (1990)	
C80	HOBART, The Immune System: A Course on the Molecular and Cellular Basis of immunity, Blackwell Scientific Pubs, Page 7 (1975)	
C81	HOLTMANN et al., Down Regulation of the Receptors For Tumor Necrosis Factor By Interleukin 1 and 4 β -Phorbol-12-Myristate-13-Acetate, J. Immunol., 139:1161-1167 (1987).	
C82	HSU et al., Differential Expression and Ligand Binding Properties of Tumor Necrosis Factor Receptor Chimeric Mutants, J. Biol. Chem., 268:16430-16436 (1992)	
C83	IDZERDA et al., Human Interleukin 4 Receptor Confers Biological Responsiveness And Defines A Novel Receptor Superfamily, J. Exp. Med., 171:861-873 (1990)	
C84	IMAMURA et al., Expression Of Tumor Necrosis Factor Receptors On Human Monocytes And Internalization Of Receptor Bound Ligand, J. Immunol., 139:2989-2992 (1987)	
C85	ISHIKURA et al., Differential Biologic Effects Resulting From Bimodal Binding of Recombinant Human Tumor Necrosis Factor to Myeloid Leukemia Cells, Blood, 73:419-424 (1989)	
C86	ISRAEL et al., Binding Of Human TNF- α To High-Affinity Cell Surface Receptors: Effect Of IFN, Immunology Letters, 12:217-224 (1986)	
C87	JACOBS et al., Pharmacokinetic Parameters and Biodistribution of Soluble Cytokine Receptors, International Review of Experimental Pathology, 34B:123-135 (1993)	
C88	JONES et al, Structure of Tumour Necrosis Factor, Nature, 338:225-228 (1989)	
C89	KACZMARSKI et al., The Cytokine Receptor Superfamily, Blood Reviews, 5:193-203 (1991)	
C90	KAUSHANSKY, Structure-Function Relationships of the Hematopoietic Growth Factors, Proteins: Structure, Function & Genetics, 12:1-9 (1992)	
C91	KEEGAN et al., The Interleukin-4 Receptor: Signal Transduction by a Hematopoietin Receptor, Journal of Leukocyte Biology, 55:272-279 (1994)	
C92	KEEGAN et al., Interleukin 4 Receptor: Signaling Mechanisms, Immunology Today, 15:423-432 (1994)	
C93	KLEINAU et al., Importance of CD23 for Collagen-Induced Arthritis: Delayed Onset and Reduced Severity in CD23-Deficient Mice, J. Immunol., 162:4266-4270 (1999)	
C94	KLINKERT et al., TNF- α Receptor Fusion Protein Prevents Experimental Auto-Immune Encephalomyelitis and Demyelination in Lewis Rats: an Overview, The Journal of Neuroimmunology, 72:163-168 (1997).	
C95	KOHNO et al., A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor, Proc. Natl. Acad. Sci. USA, 87:8331-8335 (1990)	
C96	KRUSE et al., Conversion of Human Interleukin-4 Into a High Affinity Antagonist by a Single Amino Acid Replacement, The EMBO Journal, 11:3237-3244 (1992)	
C97	KULL et al., Cellular Receptor for ¹²⁵ I-Labeled Tumor Necrosis Factor: Specific Binding, Affinity Labeling, and Relationship to Sensitivity, Proc. Natl. Acad. Sci. USA, 82:5756-5760 (1985)	
C98	LANDOLFI, A Chimeric IL-2/Ig Molecule Possesses The Functional Activity Of Both Proteins, J. Immunol., 146:915-919 (1991)	
Examiner Signature		Date Considered



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
				Attorney Docket Number	01017/40451C
Sheet	6	of	8		

C99	LANGNER et al., Structural and Functional Analysis of a TNF Receptor-Immunoglobulin Fusion Protein, New Advances on Cytokines, 349-354 (1992)	
C100	LEBERTHON et al., Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate, Cancer Research, 51:2694-2698 (1991)	
C101	LESSLAUER et al., Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-Induced Lethality, Eur. J. Immunol., 21:2883-2886 (1991)	
C102	LIABAKK et al., A Rapid and Sensitive Immunoassay for Tumor Necrosis Factor Using Magnetic Monodisperse Polymer Particles, Journal of Immunological Methods, 134:253-259 (1990)	
C103	LOETSCHER et al., Efficacy of a Chimeric TNFR-IgG Fusion Protein to Inhibit TNF Activity in Animal Models of Septic Shock, Endotoxin Research Series, 2:455-462 (1993)	
C104	LOETSCHER et al., Two distinct human TNF receptors: purification, molecular cloning and expression, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3 rd International Conference	
C105	MALISZEWSKI et al., Cytokine Receptors And B Cell Functions: Recombinant Soluble Receptors Specifically Inhibit IL-1 and IL-4 Induced Cell Activities In Vitro, J. Immunol., 144:3028-3033 (1990)	
C106	MOHLER et al., Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists, J. Immunol., 151:1548-1561 (1993)	
C107	MORI et al., Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice, J. Immunol., 157:3178-3182 (1996)	
C108	MORRISSEY et al., Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade, Cell, 50:129-135 (1987)	
C109	MORRISON, In Vitro Antibodies: Strategies for Production and Application, Annu. Rev. Immunol., 10:239-265 (1992)	
C110	MOSLEY et al., The Murine Interleukin-4 Receptor: Molecular Cloning and Characterization of Secreted and Membrane Bound Forms, Cell, 59:335-348 (1989)	
C111	NOPHAR et al., Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor, The EMBO Journal, 9:3269-3278 (1990)	
C112	NOVOTNY et al., A Soluble, Single-Chain T-Cell Receptor Fragment Endowed With Antigen-Combining Properties, Proc. Natl. Acad. Sci. USA, 88:8646-8650 (1991)	
C113	OKAYAMA et al., High-Efficiency Cloning of Full-Length cDNA, Molecular and Cellular Biology, 2:161-170 (1982)	
C114	OKAYAMA et al., A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells, Molecular and Cellular Biology, 3:280-289 (1983)	
C115	OLD, Tumor Necrosis Factor, 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 1-30 (1989)	
C116	PABORSKY et al., Purification of Recombinant Human Tissue Factor, Biochemistry, 28:8072-8077 (1989)	
C117	PARRILLO, Pathogenetic Mechanisms of Septic Shock, New Eng. J. Med., 328:1471-1477 (1993)	
C118	PEETRE et al., A Tumor Necrosis Factor Binding Protein is Present in Human Biological Fluids, Eur. J. Haematol. 41:414-419 (1988)	
C119	PENNICA et al., Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin, Nature, 312:724-729 (1984).	
C120	PEPPEL et al., Chimaeric TNF-Receptor - IgG Molecule Acts As Soluble Inhibitor Of TNF Mediated Cytotoxicity, J. Cell. Biochem., Supp. 15F:439 (1991)	

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	7	of	8	Attorney Docket Number	01017/40451C

C121	PIGUET et al., Evolution of Collagen Arthritis in Mice is Arrested by Treatment With Anti-Tumor Necrosis (TNF) Antibody or a Recombinant Soluble TNF Receptor, Immunology, 77 (4):510-514 (1992)	
C122	REDFIELD et al., Secondary Structure and Topology of Human Interleukin 4 in Solution, Biochemistry, 30:11029-11035 (1991)	
C123	RUBIN, Binding Receptor Characters Zako and Expression, and Intracellular Events. 2nd Intl Conference on Tumor Necrosis Factor & Related Cytokines, Napa, CA, 94-96 (1989)	
C124	RUDDLE et al., An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis, J. Exp. Med., 172:1193-1200 (1990)	
C125	RUTKA et al., The Effects of Human Recombinant Tumor Necrosis Factor on Glioma-Derived Cell Lines: Cellular Proliferation, Cytotoxicity, Morphological and Radioreceptor Studies, Int. J. Cancer., 41:573-582 (1988)	
C126	SAXNE et al., Detection of Tumor Necrosis Factor α But Not Tumor Necrosis Factor β in Rheumatoid Arthritis Synovial Fluid and Serum, Arthritis & Rheumatism, 31:1041-1045 (1988)	
C127	SCALLON et al., Functional Comparisons Of Different Tumour Necrosis Factor Receptor/IgG Fusion Proteins, Cytokine, 7:759-770 (1995)	
C128	SCARPATI et al., Human Tissue Factor: cDNA Sequence and Chromosome Localization of the Gene, Biochemistry, 26:5234-5238 (1987)	
C129	SCHLEIFFENBAUM et al., The Tumor Necrosis Factor Receptor and Human Neutrophil Function, J. Clin. Invest., 86:184-195 (1990)	
C130	SCHNEE et al., Construction and Expression of a Recombinant Antibody-Targeted Plasminogen Activator, Proc. Natl. Acad. Sci. USA, 84:6904-6908 (1987)	
C131	SECKINGER et al., A Human Inhibitor Of Tumor Necrosis Factor α , J. Exp. Med. 167:1511-1516 (1988)	
C132	SHALABY et al., Receptor Binding and Activation of Polymorphonuclear Neutrophils by Tumor Necrosis Factor-Alpha, Journal of Leukocyte Biology, 41:196-204 (1987)	
C133	SHALABY et al., Binding and Regulation of Cellular Function by Monoclonal antibodies Against Human Tumor Necrosis Factor Receptors, J. Exp. Med. 172: 1517-1520 (1990)	
C134	SHEEHAN et al., Generation and Characterization of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors, Journal of Immunology, 142:3884-3893 (1989)	
C135	SHIN et al., Expression and Characterization of an Antibody Binding Specificity Joined to Insulin-Like Growth Factor 1: Potential Applications for Cellular Targeting, Proc. Natl. Acad. Sci., 87:5322-5326 (1990)	
C136	SIMS et al., cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily, Science, 241:585-589 (1988).	
C137	SIMS et al., Cloning the Interleukin 1 Receptor From Human T Cells, Proc. Natl. Acad. Sci., 86:8946-8950 (1989)	
C138	SMITH et al., The Active Form of Tumor Necrosis Factor Is a Trimer, J. Biol. Chem., 262:6951-6954 (1987)	
C139	SMITH et al., Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen, Science, 238:1704-1707 (1987)	
C140	SMITH et al., Multimeric Structure of the Tumor Necrosis Factor Receptor of HeLa Cells, J. Biol. Chem., 264:14646-14652 (1989)	
C141	SPICER et al., Isolation of cDNA Clones Coding for Human Tissue Factor: Primary Structure of the Protein and cDNA, Proc. Natl. Acad. Sci., 84:5148-5152 (1987)	
C142	STAINES et al., Collagen Arthritis-What Can It Teach Us?, British Journal of Rheumatology, 33:798-807 (1994)	
C143	STRADER et al., Structural Basis of β -Adrenergic Receptor Function, The FASEB Journal, 3:1825-1832 (1989)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	08/444,791-Conf. #5613
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1644
				Examiner Name	R. Schwadron, Ph.D.
Sheet	8	of	8	Attorney Docket Number	01017/40451C

C144	SUGGS et al., Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human β_2 -Microglobulin, Proc. Natl. Acad. Sci. U.S.A., 78:6613-6617 (1981)	
C145	TAUBER et al., Toxicity in Neuronal Cells Caused by Cerebrospinal Fluid from Pneumococcal and Gram-Negative Meningitis, The Journal of Infectious Diseases, 166:1045-1050 (1992)	
C146	THOMA et al., Identification of a 60-kD Tumor Necrosis Factor (TNF) Receptor as the Major Signal Transducing Component in TNF Responses, J. Exp. Med. 172: 1019-23 (1990)	
C147	TSUJIMOTO et al., Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells, Archives of Biochemistry and Biophysics, 249:563-568 (1986)	
C148	TSUJIMOTO et al., Interferon- γ Enhances Expression of Cellular Receptors for Tumor Necrosis Factor, J. Immunol., 136:2441-2444 (1986)	
C149	TSUJIMOTO et al., Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells, Proc. Natl. Acad. Sci. 82: 7626-30 (1985)	
C150	ULICH et al., Intratracheal Administration of Endotoxin and Cytokines, Clinical Immunology & Immunopathology., 72:137-140 (1994)	
C151	UNGLAUB et al., Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators, J. Exp. Med. 166:1788-1797 (1987)	
C152	VAN DER POLL et al., Pretreatment with a 55-kDa Tumor Necrosis Factor Receptor-Immunoglobulin Fusion Protein Attenuates Activation of Coagulation, but not of Fibrinolysis, during Lethal Bacteremia in Baboons, The Journal of Infectious Diseases., 176:296-299 (1997)	
C153	VAN ZEE et al., Protection Against Lethal <i>Escherichia coli</i> Bacteremia in Baboons (<i>Papio anubis</i>) by Pretreatment With a 55-kDa TNF Receptor (CD120a)-Ig Fusion Protein, Ro 45-2081, J. Immunol., 156:2221-2230 (1996)	
C154	WALLACH et al., Soluble and Cell Surface Receptors for Tumor Necrosis Factor, Progress, Inflammation Research & Therapy, 51-57 (1991)	
C155	WALLACH et al., Cell surface and soluble TNF receptors, in Tumor Necrosis Factor: Structure-Function Relationship and Clinical Application, (3 rd International Conference on Tumor Necrosis Factor and Related Cytokines, Makuhari, Chiba, Nov. 21-25, 1990), Osawa and Bonavida, eds., Basel, Karger, pp 47-57 (1992)	
C156	WILKS, The CD4 Receptor: Post Binding Events, Conformational Change and the Second Site, Molec. Aspects Med., 12:255-265 (1991)	
C157	YAMASAKI et al., Cloning and Expression of the Human Interleukin-6 (BSF-2/IFN β 2) Receptor, Science, 241:825-282 (1988).	
C158	YONEHARA et al., A Cell-Killing Monoclonal Antibody (Anti-Fas) to a Cell Surface Antigen Co-Downregulated With the Receptor of Tumor Necrosis Factor, J. Exp. Med., 169:1747-1765 (1989)	
C159	YOSHIE et al., Binding and Crosslinking of ¹²⁵ I-Labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors, J. Biochem., 100: 531-541(1986)	
C160	BROWER et al. Roche's RA Drug Crippled, Nature Biotechnology, 15:1325 (1997)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--